Search
Cardiolipin Biosynthesis CL(10:0/20:0/i-20:0/i-21:0)
smpdb.ca/view/SMP0179027MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/a-13:0/20:0/i-20:0)
smpdb.ca/view/SMP0179307MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/a-15:0/20:0/i-20:0)
smpdb.ca/view/SMP0179690MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-13:0/20:0/i-20:0)
smpdb.ca/view/SMP0180775MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-15:0/20:0/i-20:0)
smpdb.ca/view/SMP0181480MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-20:0/i-20:0/21:0)
smpdb.ca/view/SMP0182327MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-20:0/i-20:0/22:0)
smpdb.ca/view/SMP0182328MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral
Synonyms: N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO, 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-Categories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds, 1-RingOxidronic acid
go.drugbank.com/drugs/DB14159ApprovedProducts: TECHNESCAN HDP FOR INJECTION 3 mg/vial, TECHNESCAN HDP POWDER FOR INJECTION 3.15 mg/vialDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facili...
Products: Dalbavancin Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Dalbavancin ratiopharm 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung